Nektar Therapeutics (NKTR) Capital Expenditures Growth (5y) (2015 - 2026)
Nektar Therapeutics (NKTR) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | Nektar Therapeutics | 1.73 Bn | 1.16 Bn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.75% |
| Dec 31, 2025 | -59.98% |
| Sep 30, 2025 | -43.09% |
| Jun 30, 2025 | -57.58% |
| Mar 31, 2025 | -70.53% |
| Dec 31, 2024 | -34.02% |
| Sep 30, 2024 | -34.01% |
| Jun 30, 2024 | -56.28% |
| Mar 31, 2024 | -51.16% |
| Dec 31, 2023 | -51.34% |
| Sep 30, 2023 | -55.17% |
| Jun 30, 2023 | -43.22% |
| Mar 31, 2023 | -15.16% |
| Dec 31, 2022 | -26.54% |
| Sep 30, 2022 | -28.05% |
| Jun 30, 2022 | -19.13% |
| Mar 31, 2022 | 0.55% |
| Dec 31, 2021 | 17.34% |
| Sep 30, 2021 | 42.09% |
| Jun 30, 2021 | 16.11% |